Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals strong financial performance with a significant revenue increase, improved operating and EBITDA losses, and a higher cash balance. The Q&A highlights strategic growth plans, competitive positioning, and market expansion. Despite some uncertainties in management responses, the overall sentiment is positive due to strong growth drivers, increased prescriber adoption, and anticipated profitability by year-end. The expected rise in GTN discounts and SG&A expenses is offset by the positive revenue and demand trends, suggesting a likely positive stock price movement over the next two weeks.

Key Financial Performance

Net Product Revenue (Q4 2025) $9.1 million, a 28% increase from $7.1 million in Q3 2025. The increase was driven by a 129% rise in prescriptions for ZELSUVMI and reduced inventory stocking compared to Q3.

Cost of Goods Sold (Q4 2025) $1.7 million, down from $4.0 million in Q3 2025. The decline was due to the write-off of an out-of-specification API batch in Q3 and the inclusion of fair value step-up inventory costs.

Prescriptions for ZELSUVMI (Q4 2025) 6,232 units, a 129% increase from 2,716 units in Q3 2025. The growth was attributed to strong patient demand and increased prescriber adoption.

Unique Prescribers for ZELSUVMI (Q4 2025) 2,712 unique prescribers, up from 1,169 in Q3 2025. This reflects growing awareness and adoption among healthcare providers.

Gross-to-Net Adjustments (GTNs) (Q4 2025) 28.7%, in line with expectations. GTNs include distribution costs, Medicaid discounts, payer contracts, and co-pay voucher programs.

Operating Loss (Q4 2025) $12.0 million, an improvement from $15.4 million in Q3 2025. The improvement was due to increased revenue and controlled SG&A expenses.

Adjusted EBITDA Loss (Q4 2025) $9.0 million, an improvement from $11.5 million in Q3 2025. This reflects better financial performance driven by revenue growth and cost management.

Cash Balance (End of Q4 2025) $18.0 million, up from $14.2 million at the end of Q3 2025. The increase was supported by convertible note issuance and revenue growth.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

ZELSUVMI launch success: ZELSUVMI, a novel topical nitric oxide releasing product for molluscum contagiosum (MC), saw a 129% increase in prescriptions from Q3 to Q4 2025, with net product revenue rising from $7.1 million to $9.1 million. It is the first FDA-approved at-home treatment for MC, providing significant patient convenience and addressing a large unmet need.

New product acquisitions: Pelthos acquired two FDA-approved products: Xepi, a topical treatment for impetigo, and Xeglyze, a treatment for head lice. Both products are complementary to ZELSUVMI and target similar patient demographics, leveraging existing commercial infrastructure. Xepi is expected to launch in January 2027, and Xeglyze in late Q2 2027.

Market demand for ZELSUVMI: ZELSUVMI is addressing a significant market need with 16 million people in the U.S. affected by MC and 6 million new cases annually. The product has achieved 59% commercial insurance coverage and 99% Medicaid coverage, with strong adoption by healthcare providers and patients.

Expansion of sales force: Pelthos expanded its sales team by 14 territory managers in new metropolitan areas, leading to increased prescriptions and market penetration.

Operational efficiencies: Pelthos reduced its quarterly operating loss from $15.4 million in Q3 to $12.0 million in Q4 2025. Adjusted EBITDA loss also improved from $11.5 million to $9.0 million. The company is managing inventory levels effectively and maintaining financial discipline.

Financial strengthening: Pelthos secured $18 million in convertible notes and $30 million in term debt, bolstering its cash position to support product launches and operational growth.

Strategic product portfolio expansion: The acquisition of Xepi and Xeglyze aligns with Pelthos' strategy to build a complementary product portfolio, leveraging existing infrastructure for operational and financial efficiency.

Focus on long-term growth: Pelthos is prioritizing sustainable revenue growth and profitability through disciplined financial management and strategic market positioning.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Market Conditions: The company faces challenges in managing inventory levels and ensuring product availability, as evidenced by the slight increase in total inventory in the channel and the need to manage days on hand.

Regulatory Hurdles: The company must navigate regulatory requirements for Medicaid coverage and prior authorizations, which vary by state and could impact patient access to ZELSUVMI.

Supply Chain Disruptions: The company experienced a write-off of an out-of-specification API batch in Q3 2025, highlighting potential risks in the manufacturing process.

Economic Uncertainties: The company relies on Medicaid and commercial PBM contracts, which could be affected by changes in healthcare policies or economic conditions.

Strategic Execution Risks: The company is expanding its sales force and launching new products, which requires significant investment and operational efficiency to ensure profitability.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

ZELSUVMI Launch: ZELSUVMI, a novel topical nitric oxide releasing product for molluscum contagiosum (MC), launched in Q3 2025. It is the first FDA-approved at-home treatment for MC, targeting children aged 1 year and older. The product has strong patent protection until 2035, with potential extension to 2037.

Product Acquisitions: Acquired Xepi (FDA-approved for impetigo) and Xeglyze (FDA-approved for head lice). Xepi is expected to launch in January 2027, while Xeglyze is expected to launch in late Q2 2027. Both products are complementary to ZELSUVMI and leverage existing sales infrastructure.

Sales Force Expansion: Expanded sales team by 14 territory managers in metropolitan areas, increasing coverage and driving prescription growth.

Financial Strength: Secured $18 million convertible note and $15 million term debt loan, strengthening cash balance to support growth initiatives.

Revenue Growth Expectations: ZELSUVMI prescriptions and shipments exceeded expectations in 2025, leading to increased internal expectations for 2026. The product is expected to drive significant revenue growth as it becomes the first-line treatment for MC.

Product Launch Timelines: Xepi is expected to launch in January 2027, and Xeglyze is expected to launch in late Q2 2027. Both products are anticipated to contribute to revenue growth and operational leverage.

Market Trends: Rising resistance to current treatments for impetigo and head lice supports the growth potential of Xepi and Xeglyze. ZELSUVMI is positioned to revolutionize MC treatment and expand its market share.

Operational Efficiency: The company plans to manage expenses tightly while supporting product launches and sales force expansion. Gross-to-net (GTN) adjustments are expected to stabilize in the mid-to-upper 30% range.

Profitability Path: The company aims to achieve positive cash flow and profitability through revenue growth from ZELSUVMI and new product launches, combined with disciplined expense management.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:What are the components contributing to the increase in gross-to-net (GTN) discount?

A:The increase in GTN discount is primarily driven by three components: the contract signed in December, higher utilization of co-pay cards, and slightly higher Medicaid business utilization than originally forecasted.

Q:What are the competitive dynamics between Pelthos and Ycanth?

A:Pelthos views the market as large enough for both companies to succeed. ZELSUVMI is positioned as a first-line monotherapeutic option, emphasizing its at-home treatment convenience compared to Ycanth's in-office treatment. Pelthos does not engage in counter-detailing strategies.

Q:What are the growth drivers for ZELSUVMI in 2026?

A:Growth drivers include the impact of the PBM contract, the addition of 14 sales reps, and the anticipated increase in patient visits during warmer months. The company is focusing on expanding the prescriber base and increasing depth among high-decile prescribers.

Q:What is the unaided awareness of ZELSUVMI, and how does it relate to the launch of Xepi?

A:Unaided awareness of ZELSUVMI is being driven by digital promotions and media campaigns, including YouTube commercials. ZELSUVMI will remain the primary focus in the commercial bag even after the launch of Xepi.

Q:How pronounced is the seasonality for ZELSUVMI, and what are the expectations for warmer months?

A:Seasonality is significant, with unique patient numbers being higher in warmer months (e.g., 43,000-47,500 in March-May) compared to colder months (e.g., 33,000-34,000 in November-December). Warmer months like Q2 and Q3 are expected to be high-volume periods.

Q:What is the company's strategy regarding the optimal number of products in the sales force bag?

A:The company currently has three complementary products and is open to opportunistic additions if they align with the business strategy. The focus remains on executing the ZELSUVMI launch while preparing for Xepi and Xeglyze launches.

Q:What has been the adoption trend for ZELSUVMI among pediatricians and dermatologists?

A:Adoption has been strong among dermatologists, especially pediatric dermatologists and NP/PAs. Pediatricians, who previously lacked effective treatment options, are also adopting ZELSUVMI better than expected. Pushback has been minimal and mostly related to market access.

Q:What are the expectations for gross-to-net (GTN) discount and SG&A expenses?

A:The GTN discount is expected to rise to the mid- to upper mid-30% range due to increased co-pay card usage and PBM contracts. SG&A expenses will increase slightly in Q1 due to sales team expansion and launch preparations for Xepi and Xeglyze, but will remain largely flat throughout the year.

Q:When is ZELSUVMI expected to become profitable, and what about Pelthos overall?

A:ZELSUVMI and Pelthos are expected to become profitable by the end of the year, assuming no changes to the current business plan or outlook.

Q:Review of Unclear Management Responses

A:Management avoided providing specific guidance on when ZELSUVMI or Pelthos would become profitable, only stating that profitability is expected by the end of the year under the current business plan. Additionally, there was no detailed breakdown of unaided awareness metrics for ZELSUVMI or specific data on the impact of digital promotions.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

PTHS Transcript

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Positive3-19

Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript

Unknown11-13

The earnings call presents a mixed picture. Financial performance shows strong initial demand but also significant losses. Product development highlights reliance on a few products, with risks in commercialization. Market strategy lacks clarity, and financial health is strained by recent financing. Shareholder returns were not discussed. Q&A reveals cautious optimism but also management's reluctance to provide specifics. Overall, the sentiment is neutral, with potential for both positive and negative outcomes depending on execution and market conditions.

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.